HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Amin Li Selected Research

dactolisib

3/2022BEZ235 reduction of cisplatin resistance on wild-type EGFR non-small cell lung cancer cells.
12/2021Retraction Note: The PI3K/mTOR Dual Inhibitor BEZ235 Nanoparticles Improve Radiosensitization of Hepatoma Cells Through Apoptosis and Regulation DNA Repair Pathway.
1/2021BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy.
4/2020Anti-GPC3 Antibody-Conjugated BEZ235 Loaded Polymeric Nanoparticles (Ab-BEZ235-NP) Enhances Radiosensitivity in Hepatocellular Carcinoma Cells by Inhibition of DNA Double-Strand Break Repair.
3/2020The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation DNA repair pathway.
1/2020Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles.
1/2019BEZ235 enhances chemosensitivity of paclitaxel in hepatocellular carcinoma through inhibiting the PI3K/Akt/mTOR pathway.
1/2019BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Amin Li Research Topics

Disease

16Hepatocellular Carcinoma (Hepatoma)
01/2022 - 02/2018
15Neoplasms (Cancer)
10/2021 - 01/2018
4Liver Neoplasms (Liver Cancer)
01/2021 - 02/2018
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
03/2022 - 07/2020
1Ataxia Telangiectasia (Louis Bar Syndrome)
03/2022
1Inflammation (Inflammations)
10/2021
1Hypoxia (Hypoxemia)
01/2021
1Fibrosarcoma
01/2021
1Breast Neoplasms (Breast Cancer)
12/2018
1Lymphoma (Lymphomas)
01/2018
1Infections
01/2015
1Mycoses (Diseases, Fungus)
10/2014

Drug/Important Bio-Agent (IBA)

9Sorafenib (BAY 43-9006)FDA Link
01/2022 - 02/2018
8dactolisibIBA
03/2022 - 01/2019
4Pharmaceutical PreparationsIBA
03/2022 - 11/2018
3Phosphotransferases (Kinase)IBA
03/2022 - 01/2019
3Cisplatin (Platino)FDA LinkGeneric
03/2022 - 07/2020
2DNA (Deoxyribonucleic Acid)IBA
03/2022 - 04/2020
2ErbB Receptors (EGF Receptor)IBA
03/2022 - 09/2020
2Therapeutic UsesIBA
01/2021 - 02/2018
2gedatolisibIBA
01/2021 - 01/2019
2Oxaliplatin (Eloxatin)FDA LinkGeneric
01/2021 - 01/2019
2GlypicansIBA
11/2020 - 03/2020
2PolymersIBA
11/2020 - 02/2018
2Gefitinib (Iressa)FDA Link
09/2020 - 07/2020
2Biological ProductsIBA
03/2020 - 12/2018
2tocophersolanIBA
10/2018 - 02/2018
1lysyl- arginyl- alanyl- lysyl- alanyl- lysyl- threonyl- threonyl- lysyl- lysyl- arginine (PKCS)IBA
03/2022
1Proto-Oncogene Proteins c-akt (Protein Kinase B)IBA
03/2022
1DNA-Activated Protein KinaseIBA
03/2022
1TOR Serine-Threonine KinasesIBA
03/2022
1Trichloroethylene (Trichloroethene)IBA
10/2021
1CurcuminIBA
10/2021
1MK 2206IBA
01/2021
1LY3214996IBA
01/2021
1Proteins (Proteins, Gene)FDA Link
01/2021
1Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
01/2021
1Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
01/2021
1AntigensIBA
11/2020
1Cyclin D1IBA
11/2020
1Membrane Proteins (Integral Membrane Proteins)IBA
11/2020
1Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric
11/2020
1Fluorescein (Funduscein)FDA LinkGeneric
09/2020
1thiazolyl blueIBA
09/2020
1Annexin A5IBA
09/2020
1Tyrosine Kinase InhibitorsIBA
09/2020
1Propidium (Propidium Iodide)IBA
09/2020
1Paclitaxel (Taxol)FDA LinkGeneric
01/2019
1Maytansine (Maitansine)IBA
12/2018
1Trastuzumab (Herceptin)FDA Link
12/2018
1pluronic block copolymer P123IBA
10/2018
1Tocopherols (Tocopherol)IBA
02/2018
1polyethylene glycol 1000IBA
02/2018
1Mechanistic Target of Rapamycin Complex 1IBA
01/2018
1Rituximab (Mabthera)FDA Link
01/2018
1Mechanistic Target of Rapamycin Complex 2IBA
01/2018
1Interleukin-22 (IL-22)IBA
01/2015
1Antimicrobial PeptidesIBA
10/2014

Therapy/Procedure

3Drug Therapy (Chemotherapy)
03/2022 - 01/2019
3Therapeutics
04/2020 - 02/2018
1Biological Therapy
12/2018